Foxp3+ Treg Expanded from Patients with Established Diabetes Reduce Helios Expression while Retaining Normal Function Compared to Healthy Individuals

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Du, Weiting ^a   Shen, Yueh Wei ^a   Lee, Wen Hui ^a   Wang, Ding ^a   Paz, Sachiko ^a   Kandeel, Fouad ^a   Liu, Chih Pin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; HELIOS PROTEIN; IKAROS TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL;

ADULT; ANTIGENS, CD45; CASE-CONTROL STUDIES; CELL COUNT; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMMUNE TOLERANCE; INTERFERON-GAMMA; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84873689748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056209     Document Type: Article

References (43)

1. Eisenbarth GS, (2007) Update in type 1 diabetes. J Clin Endocrinol Metab 92: 2403-2407.
2. von Boehmer H, Melchers F, (2010) Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 11: 14-20.
3. Wing K, Sakaguchi S, (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11: 7-13.
4. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M, (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164.
5. Asano M, Toda M, Sakaguchi N, Sakaguchi S, (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184: 387-396.
6. Taylor PA, Lees CJ, Blazar BR, (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
7. Cao T, Soto A, Zhou W, Wang W, Eck S, et al. (2009) Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol 258: 65-71.
8. Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, et al. (2011) Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 11: 1148-1157.
9. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, et al. (2010) Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 90: 1321-1327.
10. Nadig SN, Wieckiewicz J, Wu DC, Warnecke G, Zhang W, et al. (2010) In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 16: 809-813.
11. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465.
12. Battaglia M, Roncarolo MG, (2011) Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol 23: 182-194.
13. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, et al. (2007) Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 104: 6335-6340.
14. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, et al. (2006) Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 55: 1571-1580.
15. Jaeckel E, Mpofu N, Saal N, Manns MP, (2008) Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm Metab Res 40: 126-136.
16. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA, (2005) Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes 54: 1407-1414.
17. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. (2005) Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99.
18. Glisic-Milosavljevic S, Waukau J, Jailwala P, Jana S, Khoo HJ, et al. (2007) At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One 2: e146.
19. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, et al. (2008) Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 57: 2341-2347.
20. Putnam AL, Vendrame F, Dotta F, Gottlieb PA, (2005) CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 24: 55-62.
21. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
22. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, et al. (2008) Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 154: 353-359.
23. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, et al. (2008) The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181: 7350-7355.
24. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, et al. (2007) No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612.
25. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, et al. (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186: 3918-3926.
26. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, et al. (2011) Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60: 2903-2913.
27. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, et al. (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58: 652-662.
28. O'Shea JJ, Paul WE, (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327: 1098-1102.
29. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, et al. (2009) The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10: 595-602.
30. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, et al. (2009) Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458: 351-356.
31. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1: S5-20.
32. Curotto de Lafaille MA, Lafaille JJ, (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
33. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, et al. (2010) Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184: 3433-3441.
34. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW, (2011) Helios expression is a marker of T cell activation and proliferation. PLoS One 6: e24226.
35. Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, et al. (2010) Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 40: 1099-1106.
36. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, et al. (2009) Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 106: 13439-13444.
37. Csorba TR, Lyon AW, Hollenberg MD, (2010) Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci 47: 51-71.
38. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, et al. (2002) Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109: 131-140.
39. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, et al. (2010) Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol 184: 4317-4326.
40. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, et al. (2001) Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 31: 1122-1131.
41. Gottschalk RA, Corse E, Allison JP, (2011) Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells. J Immunol.
42. Chen C, Lee WH, Zhong L, Liu CP, (2006) Regulatory T cells can mediate their function through the stimulation of APCs to produce immunosuppressive nitric oxide. J Immunol 176: 3449-3460.
43. Chen C, Liu CP, (2009) Regulatory function of a novel population of mouse autoantigen-specific Foxp3 regulatory T cells depends on IFN-gamma, NO, and contact with target cells. PLoS One 4: e7863.